Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting immunogenicity and safety of GSK HPV vaccine in healthy Japanese girls aged 10-15; study completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus-associated Disease
• Papillomavirus Infection

Drugs mentioned

• HPV vaccine (580299) (Human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2009-12-21